Adjuvanted recombinant zoster vaccine in solid organ transplant and hematopoietic stem-cell transplant recipients

Article Article scientifique Revue de la littérature Adjuvanted recombinant zoster vaccine in solid organ transplant and hematopoietic stem-cell transplant recipients eng 2022-07-05 2022-08-01 author Provost-Olewczynska Jean-Xavier Center for Vaccinology.,Medical Directorate, University Hospitals of Geneva. 754294 author Eberhardt Christiane Sigrid Center for Vaccinology.,Division of General Pediatrics, Department of Woman, Child and Adolescent Medicine, Faculty of Medicine.,Center for Vaccinology and Neonatal Immunology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland. 669023 Département de Pédiatrie, Gynécologie et Obstétrique (PETRI) 312-320 10.1097/QCO.0000000000000845 35849521 0951-7375 Purpose of review: Hematopoietic stem-cell (HSCT) and solid organ transplant (SOT) recipients are particularly at risk to develop herpes zoster and its complications. A recently approved nonlive, adjuvanted recombinant zoster vaccine (aRZV) is a potential candidate to provide durable prevention of herpes zoster. This review summarizes current scientific evidence and expert recommendations for its use in these populations and offers practical clinical guidance. Recent findings: Recent clinical trials have shown aRZV to be well tolerated and efficacious in the prevention of herpes zoster, even in the elderly. Data are emerging that this vaccine might also be effective in immunocompromised individuals, such as SOT and HSCT recipients. Evidence is sparse regarding optimal timing of vaccination and durability of responses. However, several specialized societies have already established expert-based aRZV immunization recommendations for these vulnerable populations. Summary: Practical considerations, safety concerns, and timing of vaccine administration vary from one immunocompromised subpopulation to another. Initial studies show that aRZV has a favorable safety and immunogenicity profile in SOT and HSCT recipients. However, data are sparse, particularly in allogeneic HSCT, and practical recommendations are mostly based on expert opinion. Additional research is needed to offer better insight on aRZV administration in immunocompromised patients. Adjuvants, Immunologic Aged Hematopoietic Stem Cell Transplantation / adverse effects Herpes Zoster / prevention & control Herpes Zoster Vaccine / adverse effects Herpesvirus 3, Human Humans Organ Transplantation / adverse effects Transplant Recipients Vaccines, Synthetic / adverse effects Dewey 616.07 Dewey 618 58 Département de pédiatrie, gynécologie et obstétrique 223 137 Département de pathologie et immunologie 21F false 143 Centre de vaccinologie et d'immunologie néonatale 177 Current opinion in infectious diseases 35 4 66e291c3-90b4-48f5-8d73-6f411ab42caf Article (Published version) Public Adjuvanted_recombinant_zoster_vacci.pdf 243964 application/pdf CC BY-4.0 74bd65236c45e9b759728f3289c3ace317e67601601fb0e011f80522f4d4e1ea openAccess Faculté de médecine / Section de médecine clinique / Département de pédiatrie, gynécologie et obstétrique Faculté de médecine / Section de médecine fondamentale / Département de pathologie et immunologie

Title	Published in	Access level	OA Policy	Year	Views	Downloads

Adjuvanted recombinant zoster vaccine in solid organ transplant and hematopoietic stem-cell transplant recipients	Current opinion in infectious diseases			2022	80	571

Archive ouverte UNIGE

Provost-Olewczynska, Jean-Xavier